A study of bone marrow angiogenesis and its correlation with serum vascular endothelial growth factor levels in acute leukaemia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20223086Keywords:
Angiogenesis, CD31, CD34, Leukaemia, Serum VEGF, vWFAbstract
Background: Angiogenesis, which is the development of new capillaries from existing blood vessels, occurs in both the developing embryo and postnatal life. The growth of solid tumours requires the development of micro vessels; therefore, tumour expansion correlates with the extent of angiogenesis.
Methods: A prospective study was conducted on bone marrow trephine biopsies of 40 new cases of acute leukaemia diagnosed on complete blood count, bone marrow aspiration examination, and flow cytometry, including 20 control cases. Micro sections were stained with immuno-histochemical stains using monoclonal antibodies to CD31, CD34 and vWF. Micro vessel density was analysed at a 400× using automated image analyser by two investigators independently. Data were calculated, tabulated and statistically analysed using statistical package for the social sciences (SPSS) statistical program version 18.
Results: A total of 1522 micro vessels were analysed using CD31 including 802 in acute myeloid leukaemia (AML), 512 in acute lymphocytic leukemia (ALL) and 208 in the control group. The bone marrow microvessel density (MVD) in acute myeloid leukaemia using CD31, CD34 and Von Willebrand factor (VWF) was 70.83±20.76, 66.48±18.99 and 60.32±18.75 respectively while MVD in acute lymphoblastic leukaemia was 62.74±21.09, 70.58±22.46 and 51.22±21.13 respectively. The study revealed significant difference between AML, ALL and normal bone marrow cases by using CD31, CD34 and vWF antibody. Serum vascular endothelial growth factor (VEGF) concentration in AML, ALL and control group was 163.74±119.03, 168.23±154.22 and 43.45±9.14 respectively.
Conclusions: Higher micro vessel density was observed in acute leukaemia. Present findings suggested the potential significance of characteristics of micro vessel density as potential prognostic marker as well as its application in improved selection of patients for anti-angiogenic and other treatments.
References
Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175-203.
Hamada J, Cavanaugh PG, Miki K, Nicolson GL. Paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component C3b. Cancer Res. 1993;53:4418-23.
Carmeliet, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2009;407:249-57.
Venkateswaran PS, Jojo A, Vidhyadharan G, Unni M. A Clinicopathological Correlation of Acute Leukaemias in relation to Immunophenotyping and Cytogenetics. Int J Collab Res Intern Med Public Health. 2012;4:1713-36.
Leukemia in children. In: Pui CH, editor. Childhood leukemias. New York: Cambridge University Press. 1991;48-51.
Neame PB, Soamboonsrup P, Browman GP. Classifying acute leukemia by Immunophenotyping: A combined FAB-immunological classification of AML. Blood. 1986;68:1355-62.
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
Mezei T, Horvath E, Turcu M, Gurzu S, Raica M, Jung I, et al. Microvascular density in non-Hodgkin B-cell lymphomas measured using digital morphometry. Rom J Morphol Embryol. 2012;53:67-71.
Aggarwal D, Srivastava G, Gupta R, Pant L, Krishan G, Singh S, et al. Angiogenesis in Non-Hodgkin’s lymphoma: An intercategory comparison of microvessel density. ISRN Haematol. 2012;12:1-5.
Risau W. Mechanism of angiogenesis. Nature. 1997;386:671-4.
Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:1-10.
Sorady EM, Elrahman AM, Bordini EM, Ghandour EA, Said EA, Deghady A, et al. Bone marrow angiogenesis in patients with haematological malignancies: Role of VEGF. J Egypt Natl Canc Inst. 2000;12:131-6.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:1-16.
DE Bont ESJM, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularisation in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296-304.
Kuzu I, Beksac M, Arat M, Celebi H, Elhan HA, Erekul S, et al. Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival. Leuk Lymphoma. 2004;45:1185-90.
Erdem F, Giindogdu M, Kiziltunc A. Serum vascular endothelial growth factor level in patients with haematological malignancies. Eur J Gen Med. 2006;3:116-20.
Barbara JB. The nature of leukemia, cytology, cytochemistry and the FAB classification of acute leukemia. In: Barbara JB, editor. Leukemia diagnosis. 4th ed. Blackwell. 2010;3.
Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-13.
Perez- Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-21.
Jothilingam P, Basu D. Dutta TK. Angiogenesis and Proliferation Index in Patients with Acute Leukemia: A Prospective Study. Bone Marrow Res. 2014;1-7.
Song Y, Tan Y, Liu L, Wang Q, Zhu J, Liu M. Levels of bone marrow micro vessel density are crucial for evaluating the status of acute myeloid leukemia. Oncol Lett. 2015;10:211-5.
Won SC, Rha SY, Hwan S, Kim HM, Lyu CJ. Clinical implication of bone marrow angiogenesis in childhood acute lymphoblastic leukemia. Blood. 2014;106:1-3.
Kalra M, Dinand V, Choudhary S, Sachdeva A, Yadav SP. Serum Vascular Endothelial Growth Factor- A Level During Induction Therapy in Children with Acute Lymphoblastic Leukemia. Indian Pediatr. 2013;50:659-62.
Chand R, Chandra H, Chandra S, Verma SK. Role of Micro vessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies. Bone Marrow Res. 2016;6:1-4.
